45 results about "Topical uses" patented technology

The invention relates to a product for topical use in the treatment of skin affected by dysbiosis. The product has a pH ranging from 5.5 to 6.5 and essentially comprises water, glycerin and at least one crosslinked polyacrylate. This product can be used as a prerequisite for the transplantation of biological material favorable to the development of a healthy cutaneous bacterial flora.

A biocompatible adhesive suitable for both internal and topical use. The adhesive is a tissue-adhesive hydrogel formed from an oxidized carboxymethylcellulose (oCMC) with aldehyde functional groups and a methacrylated methylcellulose (mMC).

The present invention provides a new silicone gel composition suitable for preparing an anti-herpes viruses product of natural origin. The new composition is capable of permeating at the target epidermis side of the skin. The new composition is capable of retaining in the target epidermis side of the skin for a certain period. The present invention also relates to the topical use of the silicone gel composition for the treatment of viruses of the herpes family at a posology regime.

To search for a new active ingredient that is effective in improvement, treatment, and prevention of periodontal disease, and to provide a periodontal disease preventive or therapeutic agent including the new active ingredient.SOLUTION: A periodontal disease preventive or therapeutic agent containing dextromethorphan and / or a salt thereof, an internal or external periodontal disease preventive or therapeutic medicine, and an oral composition for preventing or treating periodontal disease such as a patch, a liniment, a film, a dentifrice, a mouthwash, or a spray, are provided. As the salt of dextromethorphan, dextromethorphan hydrobromide is preferred.SELECTED DRAWING: Figure 2

The object of the present invention is Udonitrectag (or Negermin or MTS. IUPAC name (1S,4R,5R,7S)-3,4-dibenzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxylic acid lysine salt) and pharmaceutical formulation thereof for topical use for use in the treatment of dermatological diseases. i.e. of the skin and mucous membranes.

The present invention relates to a composition and method for solubilizing eggshell membrane at convenient rates. The present invention also relates to organoleptically acceptable products obtained therein, and to their oral or topical application to improve a disease or condition in a subject.

A method for reducing the amount of sebum produced by human skin and / or by the scalp, for preventing, reducing, slowing down, stopping, and / or attenuating the appearance of unsightly, uncomfortable, and / or unpleasant manifestations of the skin and / or scalp in humans due to the secretion of sebum includes topically applying an extract of the alga Halopteris scoparia. Cosmetic or pharmaceutical compositions, in particular dermatological compositions, for topical use, containing an extract of the alga Halopteris scoparia, are also described.

Pharmaceutical compositions for topical use containing diclofenac in the form of salt with epolamine, present at concentrations higher than 2.0% by weight are described. Such compositions provide, with respect to those currently available, a more complete absorption of the administered dose, reducing the dispersion of active ingredient and allowing treatments requiring the administration of high and accurate dosages to be carried out.

To provide a topical skin composition that has moderate viscosity while exhibiting excellent stability over time. [Solution] A composition for topical use on the skin, comprising the following components (A) to (F): (A) a polyglycerin fatty acid ester in which R in the fatty acid-derived group R-COO- is an alkyl group having 13 to 23 carbon atoms or an alkenyl group having 13 to 23 carbon atoms; (B) a polyhydric alcohol of trivalent or higher; (C) a polyhydric alcohol of divalent value; (D) an oily component that is liquid at 25°C; (E) a compound represented by formula (I), its salts and mixtures thereof; and (F) a nonionic surfactant other than component (A) and component (E) with an HLB of 4.5 to 12.0, and substantially free of water.

The invention relates to a novel topical pharmaceutical composition comprising ceftizoxime, a third-generation cephalosporin antibiotic, complexed with sulfobutyl ether-β-cyclodextrin (SBE-β-CD) to enhance solubility and stability in aqueous environments. The sterile, sprayable formulation is intended for direct topical use or dilution for the treatment and prevention of bacterial skin and wound infections. To overcome ceftizoxime's aqueous instability, the invention employs inclusion complexation with 2–10% w / v SBE-β-CD, prepared by shaking at 30°C for 72 hours followed by sterile filtration. Differential Scanning Calorimetry (DSC) confirms molecular encapsulation through suppression of the ceftizoxime melting peak, indicating loss of crystallinity. Antibacterial efficacy is demonstrated against Staphylococcus aureus and Escherichia coli using zone of inhibition assays. UV–Vis spectrophotometry at 258 nm confirms high linearity (R² = 0.998) for quantitative analysis. The formulation offers a stable, scalable, and patient-friendly alternative for localized antibiotic therapy and surgical prophylaxis with reduced systemic exposure.

The problem that this invention aims to solve is the development of a composition intended to protect the skin from ultraviolet rays and that does not have the drawbacks of the prior art. [Solution] The present invention relates to a topical composition that generates a photonic barrier from ultraviolet to visible light, comprising metal-doped crystalline bismuth oxide colloid Bi2O3.

The present invention relates to a gel or cream formulation for topical use, the formulation comprising beta-D-mannuronic acid or alpha-L-guluronic acid or a mixture of beta-D-mannuronic acid and alpha-L-guluronic acid, their oligomers or their pharmaceutically acceptable salts, where, based on 100 g of the gel or cream formulation, the content of the beta-D-mannuronic acid or alpha-L-guluronic acid or the mixture of beta-D-mannuronic acid and alpha-L-guluronic acid or alpha-L-guluronic acid or alpha-L-guluronic acid or alpha-L-guluronic acid or alpha- the total amount of beta-D-mannuronic acid or alpha-L-guluronic acid or a mixture of beta-D-mannuronic acid and alpha-L-guluronic acid, their oligomers or their pharmaceutically acceptable salts is from 0.5 g to 40 g, said formulation further comprising caffeic acid. Furthermore, the present invention relates to a gel or cream formulation for topical use in a method of treating inflammation and / or any inflammatory response and / or pain, as well as a method of preparing the gel or cream formulation.

The invention relates to a cosmetic composition in the form of an oil-in-water emulsion free of petrolatum and paraffin. This composition comprises water, at least one polyol, 45 to 70% by weight of oily emollient(s), 4 to 15% by weight of waxy consistency factor(s), and at least one emulsifying agent chosen from sucrose and fatty acid esters. This composition proves to be particularly effective for the repair of damaged skin, when applied topically.

The present invention discloses the preparation and therapeutic properties of a gel consisting of the active ingredients diclofenac sodium and lysine clonixinate, which are combined for the first time for the topical treatment of pain in musculoskeletal inflammatory processes.

The present invention relates to fast dissolving powder combinations or compositions of high molecular weight hyaluronic acid (HMW-HA) and to processes for preparing HMW-HA water-based fluid compositions comprising them such as a drinkable composition, e.g., a ready to drink (RTD) beverage or another water-based fluid product for oral use containing HMW-HA, or water-based HMW-HA spray product for topical use. The drinkable HMW-HA water-based fluid compositions, for example a RTD beverage of HMW-HA, obtained using the fast-dissolving solid combinations or compositions of the invention are useful for, but not limited to, joint health, skin care, anti-aging. The fast-dissolving solid combinations or compositions of high molecular weight hyaluronic acid (HMW-HA) of the present invention can also be advantageously used for the preparation of a water-based HMW-HA spray product (e.g., a mouth spray, a topical spray for the skin or joints, a lung spray).

The present invention provides compositions of Dodeca-2,4,6,8,10-pentaenoic acid (DDPA) prepared as a composition emulsion for topical use and methods for improving animal skin health. The compositions are useful for treating an inflammatory skin condition by the topical application of an emulsion as an ointment, a cream, a foam, or a gel.

The present invention relates to compositions comprising an IRAK4 inhibitor useful for treating dermatological disorders or conditions characterized by inflammation. The present invention also relates to methods for treating dermatological disorders or conditions.

The formulation describe the preparation of an analgesic balm which comprises camphor, menthol, thymol, essential oils; e.g., wintergreen oil, eucalyptus oil, turpentine oil & cinnamomun oil; and hard wax in petroleum jelly base. This preparation is excellent in the precutanous absorption of menthol, thymol and provides good result upon use. It is prepared for topical use and effective for stiff joint pain, sciatica, headache and deep seated muscular pain. Its result is much better than othef marketed available drugs for same purpose.

This invention relates to topical pharmaceutical preparations containing nanosystems based on Lippia sidoides Cham. (rosemary-pepper) essential oil or thymol, indicated for the treatment of inflammatory diseases. The present invention relates to topical pharmaceutical preparations containing nanosystems such as polymeric nanoparticles or nanoemulsions, based on Lippia sidoides Cham. essential oil, or the isolated compound thymol, carried in pharmaceutical preparations in liquid or semi-solid forms, indicated for the treatment of inflammatory diseases. This invention also contemplates the standardization of the essential oil used as an active ingredient in these preparations, as well as the method of preparing the nanosystems consisting of polymeric nanoparticles or nanoemulsions, as well as their compositions and their potential in the treatment of inflammatory diseases.

This patent relates to a novel phytotherapeutic compound for topical use, specially formulated for the treatment of burns. The innovation lies in the use of a formulation that combines passion fruit leaves (Passiflora sp.) and refined pork fat, providing a natural and effective approach to the management of skin burns. Passion fruit leaves are processed by infusion to extract flavonoids, known for their anti-inflammatory and antioxidant properties, which reduce inflammation and oxidative stress in damaged tissue, facilitating healing. Refined pork fat, chosen for its rich composition of essential fatty acids and its emollient properties, serves as the base for the ointment, helping to absorb the active ingredients and to form a protective barrier that minimises transepidermal water loss and protects against infections. The method of obtaining the compound involves frying the fat to extract lipids, followed by filtration for purification. Subsequently, passion fruit leaf extracts are combined with the purified fat and the mixture is evaporated until it reaches the appropriate consistency for an ointment. This composition not only accelerates the healing of burns, but also significantly alleviates the pain and discomfort associated with such injuries. The compound offers an effective and safe alternative to conventional burn treatments, standing out due to its simplicity, efficacy, and use of natural ingredients, making it particularly valuable in regions with limited access to medical resources.

The invention relates to a method for determining the suitability of a product for use in a cosmetic or pharmaceutical formulation for topical use, the product being a chemical or biochemical substance of any type (S) or a composition of chemical or biochemical substances of any type (C), the method comprising a step of suspending, in a single culture medium suitable for bacterial growth, the following species: C. xerosis, M. luteus, S. epidermidis, C. acnes and S. mitis, in order to form, in the co-culture medium, a co-culture of the consortium of bacterial strains of the five aforementioned species, in proportions close to those found on the skin; followed by a step of bringing the co-culture, in the co-culture medium, into contact with the product for a period of between seven and nine hours, and a step of calculating a score (Sc): Sc = Σ(RL species X), wherein RL species X represents the following logarithmic reduction for a given bacterial species, and a step of determining the suitability of the product for use in a cosmetic or pharmaceutical formulation for topical use, wherein the determination step consists in selecting the substance (S) or the composition (C) when the score (Sc) is less than or equal to 5 and greater than or equal to -5 and rejecting the substance (S) or the composition (C) when the score (Sc) is greater than 5 or less than -5 and the individual RL species X for each species are between -3 and 3.

The present disclosure provides a solution composition comprising about 0.5% w / v to about 30% w / v of atomoxetine and about 0.1% w / v to about 20% w / v of oxybutynin, a penetration enhancer, at least 40% w / v of an aliphatic solvent, and a film forming excipient, wherein the composition forms a washable and / or a peelable film when sprayed on a skin surface, and wherein the atomoxetine and oxybutynin do not crystallize before dermal absorption when the composition is applied to the skin surface. The disclosure also provides a method of treating obstructive sleep apnea in a subject in need thereof, the method comprising topically administering to the subject the topical compositions as described herein.

The present invention relates to compositions comprising a P-gp inducer, for topical use in preventing one or more side effects of chemotherapeutics, which chemotherapeutics are transported out of cells by P-gp. Especially chemotherapy-induced peripheral neuropathy (CIPN) is a relevant side effect to treat / avoid, since CIPN may be a dose limiting side effect of chemotherapy. The invention also relates to kits and to cancer treatment of a subgroup of patients, which subgroup has been topically pretreated with a P-gp inducer.

Method for assessing the ability of a product to preserve the skin microbiota Method for determining the suitability of a product to be used in a cosmetic or pharmaceutical formulation for topical use, said product being a chemical or biochemical substance of any nature (S) or a composition of chemical or biochemical substances of any nature (C), comprising a step of suspending in a single culture medium suitable for bacterial growth of the following species: C. xerosis, M. luteus, S. epidermidis, C. acnes and S.mitis, to form a coculture in said coculture medium, of the consortium of bacterial strains of said five aforementioned species, in proportions close to those found on the skin; followed by contacting said coculture in said coculture medium with said product for a period of between seven and nine hours, calculating a score (Sc): Sc = Σ(RLpecies X) in which RLpecies X represents the following logarithmic reduction for a given bacterial species and determining the suitability of said product to be used in a cosmetic or pharmaceutical formulation for topical use, consisting of selecting said substance (S) or said composition (C), when said score Sc is less than or equal to 5 and greater than or equal to -5 and discarding said substance (S) or said composition (C), when said score Sc is greater than 5 or less than -5 and the individual RLpecies X of each species are between -3 and 3.

A method of preventing progression of an appearance or effect of aging in a subject is provided. A method of preventing, limiting, or inhibiting injury to skin integrity in a subject is also provided. A method of substantially maintaining a state of skin integrity in a subject is further provided. A method of preventing a topographical change of a cutaneous layer of skin in a subject is still further provided. The methods comprise administering an effective amount of a preparation comprising ammonia oxidizing microorganisms to the subject. Related preparations and kits are also provided.

A powder vehicle composition for topical minoxidil in which case the formulation is a powder, combining minoxidil with a dry shampoo to assist in the growth of hair on the scalp as well as absorb excess grease and oil from the scalp. The powder vehicle of minoxidil compounded with dry shampoo serves to provide similar hair growth benefits of topical minoxidil solution or foam while also removing excess grease and oil from the scalp. The instant invention contains as ingredients: minoxidil, an alcohol, arrowroot powder, cornstarch, starch, fragrance, silica, a paraffinic hydrocarbon, an alkane, oat flour, clay, and petroleum. The powder vehicle composition provides a viable solution for people with hair styling practices that do not permit the hair to become wet with liquid or foam on a daily basis.

1. Name of the product of this design: Main body of a liquid or particle dosage metering device. 2. Purpose of this design product: Overall purpose: used to measure the dosage of liquid or particles. Topical use: Body of a liquid or granular dose metering device. 3. The key point of the design of this product lies in its shape. 4. The picture or photo that best illustrates the design points: three-dimensional picture. 5. Other circumstances that require explanation: The portion indicated by the dotted line in the view does not constitute part of the design for which protection is sought.

It is an object of the present disclosure to provide a formulation for injectable and topical collagenase, which will have extended residence time for the drug at the therapeutic targeted area for the indication being treated. It is a further object of the disclosure to provide a slow release formulation for collagenase, which is compatible with the active ingredient and does not adversely affect its activity. Still a further object of the disclosure is to provide an injectable formulation for collagenase which can be effectively administered to a patient with a small size needle without exhibiting pre-gelation, which would interfere with the ability to deliver the required dose for treatment. Still a further object of the disclosure is to provide a water-based topical formulation for collagenase which will be more compatible with other topically used medications to achieve better results.

The invention relates to a new topical nasal pharmaceutical composition for the treatment and prophylaxis of Rhinosinusitis (RS), comprising a homogeneous aqueous suspension with a therapeutically effective amount of the following well-known active ingredients: Rifamycin, an antibiotic and anti-inflammatory agent for topical or local use; fluticasone propionate, an anti-inflammatory agent for local use; optionally, oxymetazoline hydrochloride, a decongestant; and bacterial antigens, local immunostimulants; 0.9% saline solution, a vehicle; and pharmaceutically acceptable excipients q.s., which are formulated for topical administration via nasal spray. The combination of these compounds produces synergy, resulting in a greater local antibiotic, anti-inflammatory, decongestant and immunomodulatory effect at the specific site of action. Its effectiveness in chronic rhinosinusitis is particularly notable in low doses. So is its good tolerance, absence of adverse effects, and ease of application. No rebound congestion has been reported with prolonged use.